Título: Pós-Doutorado
E-mail: [email protected]
Lattes: http://lattes.cnpq.br/9322677300788116
Bolsa produtividade CNPq : PQ 1D
Orcid: ID 0000-0002-3682-4517 – https://orcid.org/0000-0002-3682-4517
Scopus: ID  7004219620 – https://www.scopus.com/authid/detail.uri?authorId=7004219620
Google scholar: ID a8E84tgAAAAJ – https://scholar.google.com.br/citations?user=a8E84tgAAAAJ&hl=pt-BR
Research ID: C-2878-2012 – https://publons.com/researcher/1354897/samuel-shinjo/

Line of research:

Systemic autoimmune myopathies: from bench to bedside

Summary

Systemic autoimmune myopathies (SAM), or idiopathic inflammatory myopathies, are a set of acquired muscle diseases composed of dermatomyositis, polymyositis, inclusion body myositis, antisynthetase syndrome, and immune-mediated necrotizing myopathy, among others.

Our objective is the translational integration of basic to clinical area research and vice versa, aiming to bring benefits to the community as a whole. In this context, the group presents a broad range of SAM-related activities: (a) characterization of autoantibody reactivity (myositis-specific and associated) and of serum cytokines (proinflammatory and angiogenesis) and their expression in muscle tissues; (b) drug intervention: treat-to-target (T2T) and the role of statins; (c) non-drug intervention: safety and relevance of physical exercise and non-invasive neuromodulation; (d) addressing psychological and work aspects; (e) addressing comorbidities, especially related to cardiovascular diseases and their risk factors; (f) participation in the national and international SAM registry (Brazilian, Latin American and European: Euromyositis and AENEAS).

Activities

  • Inflammatory Myopathies Laboratory, LIM17, Rheumatology Department (FMUSP), SP
  • Inflammatory Myopathies Outpatient Clinic, Rheumatology Service (HCFMUSP), SP

Relevant articles:

  1. Pires Borges IB, de Oliveira DS, Misse RG, Dos Santos AM, Hong VAC, Bortolotto LA, Shinjo SK. Safety of Atorvastatin in Patients With Stable Systemic Autoimmune Myopathies: A Pilot Prospective Study. J Clin Rheumatol. 2020 Jan 24. doi:10.1097/RHU.0000000000001276.
  2. de Souza FHC, de Araújo DB, Vilela VS, Simões RS, Bernardo WM, Frank TA, da Cunha BM, Shinjo SK. The Brazilian Society of Rheumatology recommendations on investigation and diagnosis of systemic autoimmune myopathies. Adv Rheumatol. 2019 Oct 10;59(1):42. doi: 10.1186/s42358-019-0085-5.
  3. de Souza JM, Hoff LS, Shinjo SK. Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies. Rheumatol Int. 2019 Jul;39(7):1201-1212. doi: 10.1007/s00296-019-04254-3.
  4. de Souza JM, de Oliveira DS, Perin LA, Misse RG, Dos Santos AM, Gualano B, de Sá Pinto AL, Roschel H, Lima FR, Shinjo SK. Feasibility, safety and efficacy of exercise training in immune-mediated necrotising myopathies: a quasi-experimental prospective study. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):235-241.
  5. Shinjo SK, Nascimento JJ, Marie SK. The effect of prior corticosteroid use in muscle biopsies from patients with dermatomyositis. Clin Exp Rheumatol. 2015 May-Jun;33(3):336-40.